|Articles|March 1, 2010
Patient-centred research provides a better understanding of the impact of bottle modifications on glaucoma patients
Sponsored Feature. Xalatan® is to become available across Europe in a newly designed bottle. So what does that mean and what lies behind that decision?
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Port Delivery System Therapies in Retinal Vascular Diseases
4
Safety Considerations in Retinal Vascular Diseases
5


















